- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04213456
Double Blind, Randomized, Placebo Controlled Pilot Study to Evaluate the Effect of Nutritional Supplementation on Physical Activity Performance of Young Soccer Players
Research has clearly shown that lacking sufficient calories, macro- and micro-nutrients may impair an athlete's training adaptations, while athletes who consume a balanced diet that meets energy needs can enhance physiological training adaptations. Maintaining an energy and nutrient deficient diet during training may lead to loss of muscle mass, strength, and bone mineral density, in addition to an increased susceptibility to illness and injuries, disturbances in immune, endocrine and reproductive function, and an increased prevalence of overreaching and/or overtraining. In children and adolescent athletes, an insufficient diet may additionally result in impaired physical growth. Incorporating good dietary practices as part of a training program is one way to help optimize training adaptations and prevent overtraining.
Based on this, nutritional supplementation is an effective and safe approach for attaining the high nutritional requirements of adolescent athletes, to help them maintain healthy growth. Nutritional supplementation could also improve their body composition, sport performance and general health. The primary objective of the proposed study is to evaluate the effect of dietary supplement versus placebo on growth and physical activity performance in young athletes. A total of 50 young soccer players (25 in each group) will participate in this Double blind, randomized, placebo controlled study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Petach-Tikva, Israel, 4920235
- Schnider Children's medical center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Young soccer players aged 8-15 years old
Exclusion Criteria:
- Diagnosis of GH Deficiency or treatment with GH
- Any known chronic disease or dysmorphic syndrome including: organic brain diseases, neurological disease, past or current malignancy, chronic cardiac, renal or pulmonary problems, gastrointestinal disease including malabsorption and bone dysplasia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nutritional supplementation
Powder added to water,high protein and multi vitamin and minerals
|
Powder added to water,high protein and multi vitamins and minerals
|
|
Placebo Comparator: Placebo
Low caloric formula (Powder added to water), without added vitamins and minerals.
|
Low caloric formula (Powder added to water), without added vitamins and minerals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Height SDS (standard deviation score)
Time Frame: at 4 months
|
Change in standard deviation score of participant's height between baseline and 4 months
|
at 4 months
|
|
10m sprint score
Time Frame: at 4 months
|
Change in 10m sprint score between baseline and 4 months (test the speed and acceleration of the player)
|
at 4 months
|
|
20m sprint score
Time Frame: at 4 months
|
Change in 20m sprint score between baseline and 4 months (test the speed and acceleration of the player)
|
at 4 months
|
|
Countermovement Jump (CMJ) score
Time Frame: at 4 months
|
Change in Countermovement Jump (CMJ) score between baseline and 4 months (assess explosive strength of the lower extremity muscles)
|
at 4 months
|
|
Agility test score
Time Frame: at 4 months
|
Change in Agility test score between baseline and 4 months(agility is the ability to change the direction of the body rapidly and is a result of a combination of strength, speed, balance and coordination)
|
at 4 months
|
|
The Yo-Yo Intermittent Recovery Test Level 1 (Yo-Yo IR1) score
Time Frame: at 4 months
|
Change in the Yo-Yo IR1 score between baseline and 4 months (The Yo-Yo IR test measure the ability to recover from intense exercise)
|
at 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
weight-SDS
Time Frame: at 4 months
|
Change in standard deviation score of subject's weight between baseline and 4 months
|
at 4 months
|
|
BMI-SDS
Time Frame: at 4 months
|
Change in standard deviation score of subject's BMI between baseline and 4 months
|
at 4 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Average daily caloric intake
Time Frame: at 4 months
|
at 4 months
|
|
Average daily macronutrients intake
Time Frame: at 4 months
|
at 4 months
|
|
Average daily micronutrients intake
Time Frame: at 4 months
|
at 4 months
|
|
Average weekly duration of physical activity
Time Frame: at 4 months
|
at 4 months
|
|
Average daily duration of sedentary activity
Time Frame: at 4 months
|
at 4 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RMC0888-18ctil
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth
-
University of California, DavisCompletedGrowth Acceleration | Growth RetardationUnited States
-
Northwell HealthRecruitingGrowth | Growth Disorders | Growth Failure | Growth Hormone TreatmentUnited States
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyFrance
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in ChildrenIsrael, Denmark, Belgium, Spain, Macedonia, The Former Yugoslav Republic of, Turkey, United Kingdom, France, Slovenia, Czech Republic
-
Novo Nordisk A/SWithdrawnGrowth Hormone Disorder | Growth Hormone Deficiency in Children
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone Disorder | Adult Growth Hormone DeficiencyUnited States
-
University of CopenhagenUniversity of Aarhus; Arla FoodsCompletedGrowth Acceleration | Growth; Stunting, NutritionalDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in Children | Delivery SystemsGermany, Netherlands, Sweden
Clinical Trials on Nutritional Sport Formula
-
Abbott NutritionCompletedDiabetes Mellitus, Type 2Russian Federation
-
King Faisal Specialist Hospital & Research Centre...RecruitingCongenital Heart Disease in Children | Post-cardiac Surgery | Malnutrition, InfantSaudi Arabia
-
Chung Shan Medical UniversityCompleted
-
Abbott NutritionCompleted
-
Fundación Pública Andaluza para la Investigación...Completed
-
Abbott NutritionCompletedMalnutrition | SarcopeniaSpain, United States, Italy, Poland, Belgium, Mexico, Switzerland, United Kingdom
-
Abbott NutritionCompletedType 2 Diabetes MellitusUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnClinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Esophageal Adenocarcinoma... and other conditionsUnited States
-
Charite University, Berlin, GermanyCompletedWeight Loss | Weight Gain | Hormone DisturbanceGermany
-
Children's Hospital of Chongqing Medical UniversityThe First Hospital of Jilin University; Chengdu Women's and Children's Central... and other collaboratorsRecruitingMalnutrition, Child | Nutritional Deficiency | Malnourishment | UndernutritionChina